Work

Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation

Year: 2014

Type: article

Study design: Clinical Trial

Source: Clinical Lung Cancer

DOI: 10.1016/j.cllc.2014.06.002

Authors: Jamie E. Chaft, Anya Litvak, Maria E. Arcila, Payal Patel, Sandra P. D'Angelo, Lee M. Krug, Valerie Rusch, Alicia Mattson, Claire Coeshott, Bernard Park, David M. Apelian, Mark G. Kris, Christopher G. Azzoli

Institutions: Memorial Sloan Kettering Cancer Center, Cornell University, Weill Cornell Medicine, GlobeImmune (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2168213782

FWCI: 4.846

Cites: 17

Cited by: 79

Related to: 10